tradingkey.logo

Evotec SE

EVO
查看詳細走勢圖
3.530USD
+0.010+0.28%
收盤 02/06, 16:00美東報價延遲15分鐘
1.25B總市值
虧損本益比TTM

Evotec SE

3.530
+0.010+0.28%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.28%

5天

-3.29%

1月

-2.75%

6月

-8.55%

今年開始到現在

+14.61%

1年

-20.67%

查看詳細走勢圖

TradingKey Evotec SE股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Evotec SE當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名141/392位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為5.00。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Evotec SE評分

相關信息

行業排名
141 / 392
全市場排名
286 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Evotec SE亮點

亮點風險
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
估值高估
公司最新PE估值-7.16,處於3年歷史高位
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉0.00股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.56

分析師目標

基於 3 分析師
持有
評級
5.000
目標均價
+34.41%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Evotec SE新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Evotec SE簡介

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
公司代碼EVO
公司Evotec SE
CEOWojczewski (Christian)
網址https://www.evotec.com/
KeyAI